Is GRCE or VTVT more profitable?

vTv Therapeutics' return on equity of 3.96% beat Grace Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Grace Therapeutics N/A -14.45% -13.58% vTv Therapeutics N/A 3.96% 2.86%

Does the media refer more to GRCE or VTVT?

In the previous week, vTv Therapeutics had 1 more articles in the media than Grace Therapeutics. MarketBeat recorded 5 mentions for vTv Therapeutics and 4 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 0.50 beat vTv Therapeutics' score of 0.22 indicating that Grace Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grace Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive vTv Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is NRXP or GRCE more profitable?

NRx Pharmaceuticals' return on equity of 0.00% beat Grace Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets NRx Pharmaceuticals N/A N/A -202.92% Grace Therapeutics N/A -14.45% -13.58%

Which has higher valuation & earnings, GRCE or VANI?

Grace Therapeutics is trading at a lower price-to-earnings ratio than Vivani Medical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Grace Therapeutics N/A N/A -$7.79M -$0.48 N/A Vivani Medical N/A N/A -$26.61M -$0.40 N/A

Is GRCE or VANI more profitable?

Grace Therapeutics' return on equity of -14.45% beat Vivani Medical's return on equity. Company Net Margins Return on Equity Return on Assets Grace Therapeutics N/A -14.45% -13.58% Vivani Medical N/A -264.04% -79.85%

Does the media refer more to GRCE or VANI?

In the previous week, Vivani Medical had 1 more articles in the media than Grace Therapeutics. MarketBeat recorded 5 mentions for Vivani Medical and 4 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 0.50 beat Vivani Medical's score of 0.00 indicating that Grace Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grace Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vivani Medical 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to GRCE or FBIO?

In the previous week, Grace Therapeutics and Grace Therapeutics both had 4 articles in the media. Grace Therapeutics' average media sentiment score of 0.50 beat Fortress Biotech's score of 0.00 indicating that Grace Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grace Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fortress Biotech 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, PLYX or GRCE?

Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Grace Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Polaryx Therapeutics N/A N/A -$8.98M -$0.05 N/A Grace Therapeutics N/A N/A -$7.79M -$0.48 N/A

Is PLYX or GRCE more profitable?

Polaryx Therapeutics' return on equity of 0.00% beat Grace Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Polaryx Therapeutics N/A N/A N/A Grace Therapeutics N/A -14.45% -13.58%

Grace Therapeutics (GRCE) Competitors

$2.12 -0.02 (-0.93%)

Closing price 04:00 PM Eastern

Extended Trading

$2.16 +0.04 (+2.12%)

As of 06:34 PM Eastern

Compare

GRCE vs. VTVT, NRXP, VANI, FBIO, and PLYX

Should you buy Grace Therapeutics stock or one of its competitors? MarketBeat compares Grace Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Grace Therapeutics include vTv Therapeutics (VTVT), NRx Pharmaceuticals (NRXP), Vivani Medical (VANI), Fortress Biotech (FBIO), and Polaryx Therapeutics (PLYX). These companies are all part of the "pharmaceuticals" industry.

How does Grace Therapeutics compare to vTv Therapeutics?

Grace Therapeutics (NASDAQ:GRCE) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

In the previous week, vTv Therapeutics had 1 more articles in the media than Grace Therapeutics. MarketBeat recorded 5 mentions for vTv Therapeutics and 4 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 0.50 beat vTv Therapeutics' score of 0.22 indicating that Grace Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grace Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
vTv Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Grace Therapeutics presently has a consensus price target of $6.00, suggesting a potential upside of 183.02%. vTv Therapeutics has a consensus price target of $55.83, suggesting a potential upside of 61.32%. Given Grace Therapeutics' higher probable upside, equities analysts plainly believe Grace Therapeutics is more favorable than vTv Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grace Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
vTv Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Grace Therapeutics has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market. Comparatively, vTv Therapeutics has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market.

6.1% of Grace Therapeutics shares are owned by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are owned by institutional investors. 10.8% of Grace Therapeutics shares are owned by company insiders. Comparatively, 6.0% of vTv Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Grace Therapeutics has higher earnings, but lower revenue than vTv Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than Grace Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grace Therapeutics	N/A	N/A	-$7.79M	-$0.48	N/A
vTv Therapeutics	$1.02M	133.69	-$26.97M	-$0.93	N/A

vTv Therapeutics' return on equity of 3.96% beat Grace Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grace Therapeutics	N/A	-14.45%	-13.58%
vTv Therapeutics	N/A	3.96%	2.86%

Summary

vTv Therapeutics beats Grace Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Grace Therapeutics compare to NRx Pharmaceuticals?

NRx Pharmaceuticals (NASDAQ:NRXP) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability.

Grace Therapeutics has lower revenue, but higher earnings than NRx Pharmaceuticals. Grace Therapeutics is trading at a lower price-to-earnings ratio than NRx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NRx Pharmaceuticals	$1.23M	91.02	-$28.62M	-$1.09	N/A
Grace Therapeutics	N/A	N/A	-$7.79M	-$0.48	N/A

NRx Pharmaceuticals' return on equity of 0.00% beat Grace Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NRx Pharmaceuticals	N/A	N/A	-202.92%
Grace Therapeutics	N/A	-14.45%	-13.58%

In the previous week, Grace Therapeutics had 4 more articles in the media than NRx Pharmaceuticals. MarketBeat recorded 4 mentions for Grace Therapeutics and 0 mentions for NRx Pharmaceuticals. Grace Therapeutics' average media sentiment score of 0.50 beat NRx Pharmaceuticals' score of 0.00 indicating that Grace Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
NRx Pharmaceuticals	Neutral
Grace Therapeutics	Positive

NRx Pharmaceuticals has a beta of 2.18, meaning that its stock price is 118% more volatile than the broader market. Comparatively, Grace Therapeutics has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market.

NRx Pharmaceuticals presently has a consensus target price of $38.25, indicating a potential upside of 1,137.86%. Grace Therapeutics has a consensus target price of $6.00, indicating a potential upside of 183.02%. Given NRx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe NRx Pharmaceuticals is more favorable than Grace Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NRx Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Grace Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

4.3% of NRx Pharmaceuticals shares are owned by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are owned by institutional investors. 6.4% of NRx Pharmaceuticals shares are owned by insiders. Comparatively, 10.8% of Grace Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Grace Therapeutics beats NRx Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Grace Therapeutics compare to Vivani Medical?

Grace Therapeutics (NASDAQ:GRCE) and Vivani Medical (NASDAQ:VANI) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

Grace Therapeutics has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market. Comparatively, Vivani Medical has a beta of 2.35, meaning that its stock price is 135% more volatile than the broader market.

Grace Therapeutics is trading at a lower price-to-earnings ratio than Vivani Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grace Therapeutics	N/A	N/A	-$7.79M	-$0.48	N/A
Vivani Medical	N/A	N/A	-$26.61M	-$0.40	N/A

In the previous week, Vivani Medical had 1 more articles in the media than Grace Therapeutics. MarketBeat recorded 5 mentions for Vivani Medical and 4 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 0.50 beat Vivani Medical's score of 0.00 indicating that Grace Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grace Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vivani Medical	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

6.1% of Grace Therapeutics shares are held by institutional investors. Comparatively, 6.8% of Vivani Medical shares are held by institutional investors. 10.8% of Grace Therapeutics shares are held by insiders. Comparatively, 53.3% of Vivani Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Grace Therapeutics' return on equity of -14.45% beat Vivani Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grace Therapeutics	N/A	-14.45%	-13.58%
Vivani Medical	N/A	-264.04%	-79.85%

Grace Therapeutics currently has a consensus price target of $6.00, suggesting a potential upside of 183.02%. Vivani Medical has a consensus price target of $3.75, suggesting a potential upside of 175.74%. Given Grace Therapeutics' higher possible upside, analysts plainly believe Grace Therapeutics is more favorable than Vivani Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grace Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Vivani Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Vivani Medical beats Grace Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Grace Therapeutics compare to Fortress Biotech?

Grace Therapeutics (NASDAQ:GRCE) and Fortress Biotech (NASDAQ:FBIO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

6.1% of Grace Therapeutics shares are held by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are held by institutional investors. 10.8% of Grace Therapeutics shares are held by company insiders. Comparatively, 28.5% of Fortress Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Grace Therapeutics and Grace Therapeutics both had 4 articles in the media. Grace Therapeutics' average media sentiment score of 0.50 beat Fortress Biotech's score of 0.00 indicating that Grace Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grace Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fortress Biotech	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Grace Therapeutics has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market. Comparatively, Fortress Biotech has a beta of 1.21, suggesting that its stock price is 21% more volatile than the broader market.

Grace Therapeutics presently has a consensus target price of $6.00, suggesting a potential upside of 183.02%. Fortress Biotech has a consensus target price of $17.00, suggesting a potential upside of 513.72%. Given Fortress Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Fortress Biotech is more favorable than Grace Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grace Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Fortress Biotech has a net margin of 193.12% compared to Grace Therapeutics' net margin of 0.00%. Fortress Biotech's return on equity of 109.66% beat Grace Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grace Therapeutics	N/A	-14.45%	-13.58%
Fortress Biotech	193.12%	109.66%	45.56%

Fortress Biotech has higher revenue and earnings than Grace Therapeutics. Grace Therapeutics is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grace Therapeutics	N/A	N/A	-$7.79M	-$0.48	N/A
Fortress Biotech	$63.26M	1.45	$6.82M	$3.17	0.87

Summary

Fortress Biotech beats Grace Therapeutics on 12 of the 13 factors compared between the two stocks.

How does Grace Therapeutics compare to Polaryx Therapeutics?

Polaryx Therapeutics (NASDAQ:PLYX) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.

Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Grace Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polaryx Therapeutics	N/A	N/A	-$8.98M	-$0.05	N/A
Grace Therapeutics	N/A	N/A	-$7.79M	-$0.48	N/A

In the previous week, Grace Therapeutics had 4 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 4 mentions for Grace Therapeutics and 0 mentions for Polaryx Therapeutics. Grace Therapeutics' average media sentiment score of 0.50 beat Polaryx Therapeutics' score of 0.00 indicating that Grace Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Polaryx Therapeutics	Neutral
Grace Therapeutics	Positive

Polaryx Therapeutics currently has a consensus price target of $8.50, indicating a potential upside of 282.88%. Grace Therapeutics has a consensus price target of $6.00, indicating a potential upside of 183.02%. Given Polaryx Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Polaryx Therapeutics is more favorable than Grace Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Grace Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Polaryx Therapeutics' return on equity of 0.00% beat Grace Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polaryx Therapeutics	N/A	N/A	N/A
Grace Therapeutics	N/A	-14.45%	-13.58%

6.1% of Grace Therapeutics shares are owned by institutional investors. 45.8% of Polaryx Therapeutics shares are owned by company insiders. Comparatively, 10.8% of Grace Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Polaryx Therapeutics beats Grace Therapeutics on 7 of the 11 factors compared between the two stocks.

Get Grace Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRCE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GRCE vs. The Competition

Export

Metric	Grace Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$34.83M	$11.79B	$6.93B	$12.84B
Dividend Yield	N/A	2.73%	2.60%	9.78%
P/E Ratio	N/A	794.00	281.16	25.42
Price / Sales	N/A	750.89	591.75	95.36
Price / Cash	N/A	72.42	71.79	50.79
Price / Book	0.53	10.72	12.86	6.06
Net Income	-$7.79M	$2.82B	$3.49B	$348.34M
7 Day Performance	2.42%	2.82%	2.64%	3.03%
1 Month Performance	-16.21%	-1.31%	-2.64%	-3.04%
1 Year Performance	-28.62%	195.96%	76.00%	20.65%

Grace Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GRCE Grace Therapeutics	2.1744 of 5 stars	$2.12 -0.9%	$6.00 +183.0%	-27.7%	$34.83M	N/A	N/A	N/A	Upcoming Earnings Analyst Upgrade Gap Down
VTVT vTv Therapeutics	2.88 of 5 stars	$32.35 -1.0%	$56.67 +75.2%	+131.2%	$128.72M	$1.02M	N/A	9	Earnings Report Upcoming Earnings Analyst Forecast
NRXP NRx Pharmaceuticals	1.4824 of 5 stars	$3.15 +1.0%	$38.25 +1,114.3%	+15.9%	$113.03M	$1.23M	N/A	2	Positive News
VANI Vivani Medical	3.5223 of 5 stars	$1.28 -1.5%	$3.75 +193.0%	-8.0%	$112.11M	N/A	N/A	20	News Coverage Upcoming Earnings
FBIO Fortress Biotech	2.1868 of 5 stars	$3.13 -4.9%	$17.00 +443.1%	+46.5%	$109.29M	$63.26M	0.99	170	News Coverage Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GRCE) was last updated on 8/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Grace Therapeutics (GRCE) Competitors

GRCE vs. VTVT, NRXP, VANI, FBIO, and PLYX

How does Grace Therapeutics compare to vTv Therapeutics?

Summary

How does Grace Therapeutics compare to NRx Pharmaceuticals?

Summary

How does Grace Therapeutics compare to Vivani Medical?

Summary

How does Grace Therapeutics compare to Fortress Biotech?

Summary

How does Grace Therapeutics compare to Polaryx Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRCE vs. The Competition

Grace Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Grace Therapeutics (GRCE) Competitors

GRCE vs. VTVT, NRXP, VANI, FBIO, and PLYX

How does Grace Therapeutics compare to vTv Therapeutics?

Does the media refer more to GRCE or VTVT?

Do analysts prefer GRCE or VTVT?

Which has more risk and volatility, GRCE or VTVT?

Do institutionals & insiders hold more shares of GRCE or VTVT?

Which has stronger valuation & earnings, GRCE or VTVT?

Is GRCE or VTVT more profitable?

Summary

How does Grace Therapeutics compare to NRx Pharmaceuticals?

Which has better earnings & valuation, NRXP or GRCE?

Is NRXP or GRCE more profitable?

Does the media prefer NRXP or GRCE?

Which has more risk & volatility, NRXP or GRCE?

Do analysts rate NRXP or GRCE?

Do insiders and institutionals believe in NRXP or GRCE?

Summary

How does Grace Therapeutics compare to Vivani Medical?

Which has more risk and volatility, GRCE or VANI?

Which has higher valuation & earnings, GRCE or VANI?

Does the media refer more to GRCE or VANI?

Do institutionals & insiders hold more shares of GRCE or VANI?

Is GRCE or VANI more profitable?

Do analysts prefer GRCE or VANI?

Summary

How does Grace Therapeutics compare to Fortress Biotech?

Do institutionals & insiders believe in GRCE or FBIO?

Does the media refer more to GRCE or FBIO?

Which has more risk & volatility, GRCE or FBIO?

Do analysts recommend GRCE or FBIO?

Is GRCE or FBIO more profitable?

Which has stronger valuation and earnings, GRCE or FBIO?

Summary

How does Grace Therapeutics compare to Polaryx Therapeutics?

Which has preferable earnings & valuation, PLYX or GRCE?

Does the media favor PLYX or GRCE?

Do analysts rate PLYX or GRCE?

Is PLYX or GRCE more profitable?

Do insiders & institutionals have more ownership in PLYX or GRCE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRCE vs. The Competition

Grace Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools